ARCT (Arcturus Therapeutics Holdings) Beginning Cash Position: $232.79 Mil (As of Mar. 2026)


ARCT Arcturus Therapeutics Holdings Inc ARCT
54 GF Score
Price $6.97
GF Value $4.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings Beginning Cash Position?

Arcturus Therapeutics Holdings ARCT -2.65% 54 Beginning Cash Position is $232.79 Mil as of Mar. 2026. GuruFocus rates ARCT with a GF Score™ of 54/100 and a GF Value™ of $4.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Arcturus Therapeutics Holdings's Beginning Cash Position for the quarter that ended in Mar. 2026 was $232.79 Mil.

Arcturus Therapeutics Holdings's quarterly Beginning Cash Position declined from Sep. 2025 ($253.35 Mil) to Dec. 2025 ($237.25 Mil) and declined from Dec. 2025 ($237.25 Mil) to Mar. 2026 ($232.79 Mil).

Arcturus Therapeutics Holdings's annual Beginning Cash Position declined from Dec. 2023 ($393.98 Mil) to Dec. 2024 ($348.89 Mil) and declined from Dec. 2024 ($348.89 Mil) to Dec. 2025 ($293.91 Mil).

Arcturus Therapeutics Holdings Beginning Cash Position Related Terms

Arcturus Therapeutics Holdings Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Arcturus Therapeutics Holdings's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcturus Therapeutics Holdings Beginning Cash Position Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 463.00 372.57 393.98 348.89 293.91

Arcturus Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 293.91 273.83 253.35 237.25 232.79
ARCT
54GF Score
Arcturus Therapeutics Holdings Inc ARCT
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcturus Therapeutics Holdings Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $232.79 Mil mean?
Arcturus Therapeutics Holdings (ARCT) has a Beginning Cash Position of $232.79 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Arcturus Therapeutics Holdings and its competitors.
Is Arcturus Therapeutics Holdings' Beginning Cash Position too high?
Arcturus Therapeutics Holdings' current Beginning Cash Position is $232.79 Mil. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Beginning Cash Position compare to MDWD and UNCY?
Arcturus Therapeutics Holdings' Beginning Cash Position of $232.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Arcturus Therapeutics Holdings and its competitors. Arcturus Therapeutics Holdings's current Beginning Cash Position is $232.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.06, compared to a current price of $6.97 — trading 71.7% above its estimated fair value. The current Beginning Cash Position is $232.79 Mil. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Beginning Cash Position is $232.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $6.97 is trading 71.7% above its estimated GF Value™ of $4.06. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • Beginning Cash Position: $232.79 Mil
  • GF Value™: $4.06 vs. price of $6.97 (71.7% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score

Get the complete analysis for ARCT

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.97
Price
$4.06
GF Value